Patents by Inventor Surya K. Goli
Surya K. Goli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6018028Abstract: The present invention provides polynucleotides which identify and encode novel human proteasome subunit proteins. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PSUB. The invention also provides for the use of substantially purified PSUB, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of PSUB. Additionally, the invention provides for the use of antisense molecules to PSUB in pharmaceutical compositions for treatment of diseases associated with the expression of PSUB. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding PSUB or anti-PSUB antibodies which specifically bind to PSUB.Type: GrantFiled: August 13, 1998Date of Patent: January 25, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young, Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6010852Abstract: The present invention provides a human proton ATPase subunit (HPAS) and polynucleotides which encode HPAS. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HPAS.Type: GrantFiled: February 27, 1997Date of Patent: January 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6010879Abstract: The present invention provides a human mitochondrial chaperone protein (Hmt-GrpE) and polynucleotides which identify and encode Hmt-GrpE. The invention also provides expression vectors and host cells and a method for producing Hmt-GrpE. The invention also provides for antibodies or antagonists specifically binding Hmt-GrpE, and their use in the prevention and treatment of cancer. The invention also provides diagnostic assays. The invention also provides for the use of Hmt-GrpE in identifying antifungal and antiprotozoal therapeutics.Type: GrantFiled: November 14, 1997Date of Patent: January 4, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5998371Abstract: The present invention provides a human selenoprotein (HSEL) and polynucleotides which identify and encode HSEL. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSEL and a method for producing HSEL. The invention also provides for agonists, antibodies, or antagonists specifically binding HSEL, and their use, in the prevention and treatment of diseases associated with expression of HSEL. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSEL for the treatment of diseases associated with the expression of HSEL. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSEL.Type: GrantFiled: July 13, 1998Date of Patent: December 7, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5994112Abstract: The present invention provides a novel protein tyrosine kinase (HPTYK) and polynucleotides which identify and encode HPTYK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTYK and a method for producing HPTYK. The invention also provides pharmaceutical compositions containing HPTYK or antagonists to HPTYK, and for the use of these compositions in the treatment of diseases associated with the expression of HPTYK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPTYK for the treatment of diseases associated with the expression of HPTYK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HPTYK or antibodies which specifically bind to HPTYK.Type: GrantFiled: October 9, 1996Date of Patent: November 30, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventor: Surya K. Goli
-
Patent number: 5989883Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.Type: GrantFiled: November 20, 1998Date of Patent: November 23, 1999Inventors: Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5985638Abstract: The present invention provides a human microsomal signal peptidase subunit (HMSP) and polynucleotides which encode HMSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMSP.Type: GrantFiled: March 26, 1997Date of Patent: November 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5985635Abstract: The present invention provides human serine/threonine kinase (HSTK) and polynucleotides which identify and encode HSTK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSTK and a method for producing HSTK. The invention also provides for use of HSTK and agonists, antibodies, or antagonists specifically binding HSTK, in the prevention and treatment of diseases associated with expression of HSTK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSTK for the treatment of diseases associated with the expression of HSTK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSTK.Type: GrantFiled: November 15, 1996Date of Patent: November 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5981221Abstract: The present invention provides a human histone fusion protein (HFP) and polynucleotides which identify and encode HFP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention also provides methods for producing HFP and for treating or preventing disorders associated with expression of HFP.Type: GrantFiled: March 26, 1997Date of Patent: November 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5976528Abstract: The present invention provides a human glutathione S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.Type: GrantFiled: June 12, 1998Date of Patent: November 2, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5977320Abstract: The present invention provides a novel human phosphorylase kinase gamma subunit (HPHKG) and the polynucleotide which identifies and encodes HPHKG. The invention provides for expression vectors and host cells comprising the nucleic acid sequence encoding HPHKG. The invention also provides pharmaceutical compositions containing purified HPHKG or antisense molecules to HPHKG for the treatment of diseases associated with expression of HPHKG. The invention also includes diagnostic compositions containing the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HPHKG or anti-HPHKG antibodies which specifically bind to HPHKG, and the use of such compositions for diagnosis of disease.Type: GrantFiled: June 11, 1998Date of Patent: November 2, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5973130Abstract: The present invention provides a human Ras-like protein (RLP) and polynucleotides which identify and encode RLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing RLP and for treating or preventing disorders associated with expression of RLP.Type: GrantFiled: April 30, 1997Date of Patent: October 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli, Neil C. Corley
-
Patent number: 5972658Abstract: The present invention provides a human lung growth factor variant (LGFV) and polynucleotides which identify and encode LGFV. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding LGFV and a method for producing LGFV. The invention also provides for agonists, antibodies, or antagonists specifically binding LGFV, and their use, in the prevention and treatment of diseases associated with expression of LGFV. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding LGFV for the treatment of diseases associated with the expression of LGFV. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding LGFV.Type: GrantFiled: December 5, 1996Date of Patent: October 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5969104Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.Type: GrantFiled: July 10, 1998Date of Patent: October 19, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Benjamin Graeme Cocks, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5965706Abstract: The present invention provides a human regulator of gene transcription (HRGT) and polynucleotides which encode HRGT. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HRGT.Type: GrantFiled: April 24, 1998Date of Patent: October 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli, David G. Streeter
-
Patent number: 5962646Abstract: The present invention provides a human ATP synthase d subunit (ASYSD) and polynucleotides which encode ASYSD. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides to methods for producing ASYSD and for treating disorders associated with expression of ASYSD.Type: GrantFiled: December 16, 1998Date of Patent: October 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5962226Abstract: The present invention provides a human RNA bind-protein (HRNABP) and polynucleotides which identify and encode HRNABP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRNABP and a method for producing HRNABP. The invention also provides for antagonists or antibodies specifically binding HRNABP, and their use, in the prevention and treatment of diseases associated with expression of HRNABP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRNABP for the treatment of diseases associated with the expression of HRNABP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRNABP.Type: GrantFiled: November 26, 1996Date of Patent: October 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5958405Abstract: The present invention provides a novel protein tyrosine kinase (HPTYK) and polynucleotides which identify and encode HPTYK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTYK and a method for producing HPTYK. The invention also provides pharmaceutical compositions containing HPTYK or antagonists to HPTYK, and for the use of these compositions in the treatment of diseases associated with the expression of HPTYK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPTYK for the treatment of diseases associated with the expression of HPTYK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HPTYK or antibodies which specifically bind to HPTYK.Type: GrantFiled: July 28, 1998Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventor: Surya K. Goli
-
Patent number: 5958699Abstract: The present invention provides a human tumor-associated Kazal inhibitor (TAKI) and polynucleotides which identify and encode TAKI. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TAKI and a method for producing TAKI. The invention also provides for agonists, antibodies, or antagonists specifically binding TAKI, and their use, in the prevention and treatment of intestinal diseases including cancer. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TAKI for the treatment of diseases associated with the expression of TAKI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TAKI.Type: GrantFiled: September 9, 1998Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5955314Abstract: The present invention provides a human regulator of G-protein signaling (HRGS) and polynucleotides which identify and encode HRGS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRGS and a method for producing HRGS. The invention also provides for agonists, antibodies, or antagonists specifically binding HRGS, and their use, in the prevention and treatment of diseases associated with expression of HRGS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRGS for the treatment of diseases associated with the expression of HRGS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRGS.Type: GrantFiled: November 8, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli